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Abstract
Background: Tetralogy of Fallot (TOF) is the most commonly observed conotruncal congenital heart defect.
Treatment of these patients has evolved dramatically in the last few decades, yet a genetic explanation is lacking
for the failure of cardiac development for the majority of children with TOF. Our goal was to perform genome
wide analyses and characterize expression patterns in cardiovascular tissue (right ventricle, pulmonary valve and
pulmonary artery) obtained at the time of reconstructive surgery from 19 children with tetralogy of Fallot.
Methods: We employed genome wide gene expression microarrays to characterize cardiovascular tissue (right
ventricle, pulmonary valve and pulmonary artery) obtained at the time of reconstructive surgery from 19 children
with TOF (16 idiopathic and three with 22q11.2 deletions) and compared gene expression patterns to normally
developing subjects.
Results: We detected a signal from approximately 26,000 probes reflecting expression from about half of all genes,
ranging from 35% to 49% of array probes in the three tissues. More than 1,000 genes had a 2-fold change in
expression in the right ventricle (RV) of children with TOF as compared to the RV from matched control infants.
Most of these genes were involved in compensatory functions (e.g., hypertrophy, cardiac fibrosis and cardiac
dilation). However, two canonical pathways involved in spatial and temporal cell differentiation (WNT, p = 0.017
and Notch, p = 0.003) appeared to be generally suppressed.
Conclusions: The suppression of developmental networks may represent a remnant of a broad malfunction of
regulatory pathways leading to inaccurate boundary formation and improper structural development in the
embryonic heart. We suggest that small tissue specific genomic and/or epigenetic fluctuations could be
cumulative, leading to regulatory network disruption and failure of proper cardiac development.
Background
The heart is the first major internal organ to form during
embryogenesis, and its circulatory function is critical early
on for the viability of the embryo. The development of
integrated cardiovascular tissue is the result of multiple
cell to cell interactions involving temporal and spatial
events under genetic control. Failure of proper cellular dif-
ferentiation, migration and apoptosis results in congenital
heart disease (CHD), which is a major cause of childhood
morbidity and death and remains a substantial challenge
even in countries with advanced health care systems.
The incidence of CHD is approximately eight per 1000
live births [1] making CHD the most common birth
defect. Mendelian and chromosomal syndromes account
for about 20% of all cases of CHD. The genetic mechan-
isms underlying non-chromosomal or non-Mendelian
“sporadic” CHD, which account for the remaining 80%,
are poorly understood. A multitude of genes and genetic
networks contribute to the spatial and temporal specifica-
tion of cell lineage required for proper embryological heart
formation [2]. The molecular genetic components contri-
buting to idiopathic CHD may include accumulation of
multiple rare genomic and epigenetic variants converging
to dysregulate cardiac developmental genes leading to
mutational loading of developmental networks [3].
Although mutational loading is a credible explanation for
the genetic etiology of CHD, there is a paucity of direct
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evidence supporting this proposition. Clearly a better
understanding of the molecular genetic contributions to
CHD is needed.
Tetralogy of Fallot (TOF) is a type of conotruncal
congenital heart defect with an incidence estimated at
five to seven per 10,000 live births, thus representing
5-7% of all congenital heart lesions. The occurrence of
congenital cardiac lesions in the offspring of mothers
with tetralogy of Fallot is approximately 3.1% [4-6] sup-
porting a genetic contribution. TOF is characterized by
a malalignment of the conal septum leading to a right-
ward deviation of the aorta. This results in a large ven-
tricular septal defect and varying degrees of right
ventricular outflow tract narrowing. There is variability
in this patient population in the response to pulmonary
artery growth and right ventricular function. Characteri-
zation of underlying aberrant gene expression leading to
a better understanding of factors involved in the varied
outcomes in children with conotruncal defects, will lead
to a more tailored treatment strategy and improved
outcomes.
Studies of the role of individual genes in human car-
diac disease, as well as experimentation using animal
models have dramatically improved our understanding
of cardiac development. However, sporadic (nonmende-
lian, nonchromosomal) CHD, which account for 80% of
all CHD, poses a challenge to scientific investigation.
Epidemiological studies demonstrate an increased risk of
CHD in siblings and offspring of individuals with spora-
dic CHD indicating a contribution of genes and/or
shared environment [7]. These sporadic events are most
often inherited from unaffected parents indicating
incomplete penetrance [8]. Variable penetrance can be
explained by differences in the genetic buffering capacity
between individuals [9,10]. De novo events including
sequence alteration or copy number changes can impact
gene function or alter dosage and contribute to muta-
tional load. Recessive mutations, if homozygous, may
further destabilize regulatory networks.
Phenotypic stability is maintained by the ability of
interconnected regulatory networks to compensate for
both environmental and genetic variation. Mutational
load can be compensated for through feedback mechan-
isms that control flux through regulatory pathways thus
maintaining adequate residual function [9-13]. This con-
cept implies that if threshold levels of flux are exceeded,
compensatory mechanisms may fail, leading to inade-
quate development. Genetic studies of mutational load-
ing of cardiac developmental pathways in the mouse
model suggest limits to the buffering capacity of regula-
tory networks. When exceeded, the result is inadequate
heart development. Furthermore, compound mutations
produce phenotypes revealing the interconnected nature
of members of cardiac developmental networks
(reviewed by Bentham and Bhattacharya [3]). It is rea-
sonable to expect homologous genes to behave similarly
in humans implying that mutational loading could
exceed buffering capacity leading to improper heart
development.
Previously, five patients with TOF were compared to
patients with RV hypertrophy, and 88 genes were identi-
fied with significantly altered expression in TOF but not
altered in RV hypertrophy [14]. The authors listed poten-
tially important genes with altered expression including
SNIP, A2BP1, and KIAA1437 which were upregulated.
SNIP interacts through the BMP signaling pathway which
is essential for normal cardiac development. A2BP1
belongs to a novel gene family sharing RNA-binding
motifs expressed in the developing embryological heart.
KIAA1437 binds k-ras. K-ras deficient mice develop thin
ventricular walls and die prematurely, suggesting a
potentially important role for KIAA137in heart develop-
ment. Genes markedly downregulated in TOF included
STK33, BRDG1, and TEKT2. Sharma et al. examined four
patients with TOF with a mean age of 0.8 years [15] and
concluded that the upregulation of genes encoding VEGF
and several extracellular matrix (ECM) proteins were the
primary cause of TOF. Although the number of subjects
examined was small, both studies suggested that altered
gene expression in signaling pathways regulate heart
development and contribute to TOF. We sought to
examine gene expression variation in greater detail in tis-
sues from children with TOF with a specific interest in
determining if subtle changes in complex network beha-
vior could lead to developmental irregularities.
We collected tissue samples (e.g., right ventricle, pul-
monary artery and valve, thymus, pericardium) from a
cohort of children with a similar congenital heart defect,
tetralogy of Fallot. The surgical subjects included both
children with known chromosomal abnormalities
(22q11.2 deletion) and those with no known etiologies.
For those subjects with no known etiology to explain
TOF, we hypothesize that because of the similarity of
the defect in the outflow tract, these children share a
common developmental deficiency that may arise from
different root causes, but underlying factors converge to
disrupt proper temporal and spatial cell lineage specifi-
cation leading to developmental deficiency.
Materials
Subjects
Our subjects were children less than two years of age
with tetralogy of Fallot (TOF) requiring surgical recon-
struction. Informed consent was obtained from a parent
or legal guardian after reviewing the consent document
and having their questions answered. All proper institu-
tional review board approvals were obtained for this
study. Our subjects included 16 nondysmorphic infants
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(eight male, eight female) with idiopathic TOF cardiac
defects but without chromosome abnormalities (22q11.2
deletion). Three infants (one male, two female) with
22q11 deletion syndrome were also recruited for com-
parison of syndromic to nonsyndromic gene expression.
Comparison tissues from five (two male, three female)
normally developing infants were obtained from LifeNet
Health (http://www.lifenethealth.org, Virginia Beach,
VA). LifeNet Health is a non-profit regenerative medi-
cine company that provides bio-implants and organs for
transplantation. The control subjects were matched for
age to the study population and all control subjects
expired due to non-cardiac related causes. LifeNet
Health follows the following protocol for tissue recovery:
1) if the donor is placed in a refrigerated morgue within
12 hours of asystole, tissues can be recovered for up to
24 hours and placed in a 1-10°C sterile isotonic solution:
or 2) if the donor is not refrigerated, tissues can be
recovered for up to 15 hours and placed in a 1-10°C
sterile isotonic solution. All donor tissue was de-identi-
fied, no donor confidential information was disclosed,
and consent was obtained to use the tissue for research.
Tissue
RNA was extracted from frozen tissues using Perfect-
Pure RNA fibrous tissue Kit (5 Prime GmbH, Hamburg,
Germany), according to the manufacturer’s protocol.
The control tissues (cryopreserved pulmonary homo-
grafts) were thawed per protocol in sterile conditions.
One author (JEO) aseptically dissected samples from the
control tissue from the right ventricle, pulmonary valve,
and pulmonary artery matching what was done in sur-
gery. All subjects enrolled in this study were undergoing
surgical correction of TOF. Tissues samples obtained
during patient surgery (attending surgeons JEO and
GKL) were immediately de-identified and frozen. All tis-
sue samples removed during surgery were excised by
the performing surgeon for clinical indications utilizing
standard of care procedures. While a subset of patients
were previously palliated with a modified Blalock-
Taussig (BT) shunt, the right ventricular outflow tract
region from where the tissue was harvested had not
undergone any previous surgical manipulation.
Microarrays
Microarray data have been deposited at the Gene Expres-
sion Omnibus http://www.ncbi.nlm.nih.gov/geo/index.
html. The accession number is GSE26125. The microar-
rays were CodeLink Human Whole Genome Bioarrays
(Applied Microarrays Inc., Tempe, AZ) which contain
>54,000 probes. The detailed microarray processing pro-
tocol can be found at http://www.appliedmicroarrays.
com. Briefly, the poly (A) + RNA subpopulation (within
the total RNA population) was primed for reverse
transcription using an oligonucleotide containing a T7
RNA polymerase promoter 5’ to an oligo d(T)24
sequence. After second-strand cDNA synthesis, the
cDNA served as the template for an in vitro transcription
(IVT) reaction to produce target cRNA. The IVT was
performed in the presence of biotinylated nucleotides to
label the target cRNA. This produced an approximate
1,000-fold to 5,000-fold linear amplification of the input
mRNA.
A set of bacterial control mRNAs was included in the
CodeLink™ Expression Assay Reagent Kit (Applied
Microarrays, Tempe AZ) to act as controls for the
cDNA synthesis and IVT reactions. These controls were
added to the total RNA sample during target prepara-
tion. Each step of the CodeLink™ Expression Bioarray
processing procedure, including target preparation and
hybridization, was monitored using the control mRNAs.
Additionally, bacterial control mRNAs can be used to
estimate the sensitivity of RNA detection. Hybridization
was performed overnight in a temperature-controlled
shaking incubator with buffers supplied in the kit.
Post-hybridization processing included a stringent
wash to remove unbound and non-specifically hybridized
target molecules, a staining step with a Cy™5-Streptavidin
conjugate, and several non-stringent washing steps to
remove unbound conjugate. Following a final rinse, the
microarrays were dried by centrifugation and scanned
using an Agilent G2505B Microarray scanner (Agilent
Inc., Santa Clara, CA). Analysis of the microarrays was
performed with CodeLink Expression Analysis software
(Applied Microarrays) and results were transferred to
GeneSpring analytical software (Agilent Inc.) for further
analysis.
Occasionally, signal intensities were recorded to be
less than zero due to comparison of probe pixel inten-
sity to the local background. Signal intensities cannot be
less than 0, so the initial step in the analysis using
GeneSpring version 7 software required that all values
less than 0 be converted to a positive value, (i.e., 0.01)
as done routinely [16,17]. This was a minimal intensity
signal indicating that essentially no signal was detected.
Normalization to the median baseline signal was accom-
plished using a global scaling process for all probe sets.
Essentially, all microarrays were normalized to the med-
ian value of the control samples such that each mea-
surement for each probe, in each microarray, was
divided by the median of that probe’s measurement in
the corresponding control samples. Each measurement
was then divided by the 50th percentile of all measure-
ments in that sample. This has the effect of minimizing
discrepancies between an experiment and control base-
line array value due to variation in preparation, hybridi-
zation or staining conditions or probe array lot number.
The inclusion criteria for further analysis required a
Bittel et al. BMC Medical Genomics 2011, 4:1
http://www.biomedcentral.com/1755-8794/4/1
Page 3 of 10
‘’present’’ or ‘’marginal’’ signal in at least three of five
control arrays, or three fourths of the arrays from the
subjects with TOF. We chose to include only those
probes that had a twofold difference between the TOF
samples and controls due to the increased likelihood
that these would achieve robust differences. Further-
more, within the TOF group, all values for the probe
had to be in the same direction (up or down) relative to
the control group. Differences between mean probe sig-
nal intensity were evaluated using a Welsh t-test with-
out assuming equal variances and with a false discovery
rate (fdr) of 5% or less using Bonferroni correction for
multiple testing as undertaken in other studies [18,19].
We also examined the similarity in expression patterns
by using the expression data from the right ventricle for
detectable probes (~26,000) in an average linkage
K-means clustering algorithm. This was performed
using Pearson correlation as an expression similarity
measure to allow clustering based on expression pattern
relationships. Additionally, we were interested in identi-
fying genes with similar patterns of expression across
the three tissues, as they may have related functions.
We therefore used expression values of all 2,932 genes
with a significant change in expression in one of the
three tissues and partitioned them into classes by K-
means clustering. K-means clustering is a non-hierarchi-
cal, unsupervised, non-deterministic, and iterative
approach to grouping genes with similar expression pro-
files into clusters. K-means clustering produces clusters
of genes with a high degree of similarity within each
cluster and a low degree of similarity between clusters
so that the average behavior in each group is distinct
from any of the other groups. The number of clusters,
K, was set at nine.
We used Ingenuity Pathways analysis (IPA, Ingenuity
Systems, Inc., Redwood City, CA.) for ontological assess-
ment. IPA is a curated database and analytical bioinfor-
matic system for identifying interactions, functions and
interconnections (networks) between biological mole-
cules. For those networks that appeared to have an
excess of genes with reduced expression relative to the
controls, we estimated the confidence interval of the
proportion (i.e., is the proportion different than 50% or
random) with an associated confidence level using statis-
tical inference on the population proportion.
QRT-PCR
To validate gene expression quantitative reverse transcrip-
tion-PCR (RT-PCR) was performed on a subset of genes/
transcripts using a QuantiTect SYBR Green RT-PCR kit
(Qiagen, Valencia, CA) according to the manufacturer’s
directions and our previous experience [19]. The genes
chosen were from the WNT or Notch pathway, with sta-
tistically significant differences in microarray expression
data between the TOF and control groups in the microar-
rays data. Total RNA was isolated from tissues using a
Perfect Pure fibrous tissue RNA extraction kit (5 Prime
Inc., Gaithersburg, MD) according to the manufacturer’s
directions and quantified by spectroscopy. An equal quan-
tity of total RNA (100 ng) from each subject, together with
gene specific primers, were added to a reaction mix con-
taining all components necessary for reverse transcription
and PCR. The reaction was carried out in an ABI 7000
system (Applied Biosystems, Foster City, CA) beginning
with a 30 min step at 50°C to allow for reverse transcrip-
tion, followed by 15 min at 95°C. The intensity of the
SYBR Green fluorescence was measured at the extension
step of each of the 45 cycles of PCR The point at which
the intensity level crossed the PCR cycle threshold (CT)
was used to compare individual reactions. At least five
replicates were performed on each sample for each gene.
A dissociation curve was generated for all reactions, and
reactions were run on agarose gels to verify the presence
of a single band. Normalization of the Quantitative RT-
PCR reactions used the 2(-ΔΔCT
) method with GAPD as
the standardization gene for each sample to correct for
minor experimental error as reported previously [18-21].
Normalized CT values were averaged to produce the mean
CT value for each gene analyzed.
Results
We obtained cardiovascular tissue (right ventricle, pul-
monary valve and pulmonary artery) at the time of
reconstructive surgery from 19 children with tetralogy
of Fallot (16 idiopathic and three with 22q11.2 deletion
syndrome) and employed whole genome gene expres-
sion microarray technology to characterize variation in
gene expression patterns relative to tissues from five
normally developing comparison subjects. As there was
more than one probe per transcript, probe refers to an
individual point on the array and gene refers to a single
transcript. We detected the signal of approximately
26,000 probes on our microarrays (the signal strength
for remaining probes was below the threshold of detec-
tion) representing about 50% of the genome using RNA
isolated from the right ventricle (Table 1). Approxi-
mately 22,000 probes (41%) were detected in the valve
and artery tissue perhaps reflecting less metabolic activ-
ity in these tissues producing fewer detectable active
genes.
We estimated inter-sample variability. The column
vector B (Additional File 1, Table S1) contains the stan-
dard deviation for each sample. Each of the standard
deviations can be interpreted as the inter-sample varia-
bility. The overall pooled sample standard deviation was
1.502 for all samples. In addition we estimated the gen-
eralized variance (GV) or determinant of the covariance
matrix X. The GV value for X was 0.0023576.
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Furthermore, we examined the expression of the genes
in the 22q11.2 region, including TBX1 which did not
have a detectable signal in any of the tissues examined.
Other genes in the region (including COMT, DGCR2,
CRYBA4, ZNF74, FLJ36561, ARVCF, RUTBC2, GGT,
MMP11, Table 2) were unchanged in signal intensity in
our subjects with idiopathic TOF. As expected, half the
signal intensity was present in the three subjects with
the 22q11.2 deletion supplying evidence of the reliable
detection of gene expression levels in these tissues. We
also validated the expression of three genes from the
WNT (DVL3 and WNT5B) and Notch (DTX3) pathways
with significant differences in expression between the
TOF subjects and controls using quantitative reverse
transcription qRT-PCR. All three had good agreement
in expression levels detected by the two techniques
(Table 3).
We identified 1,062 genes in the right ventricle which
had a statistically significant change in expression of at
least 2-fold in TOF subjects relative to our control tis-
sue samples (see Figure 1). These 1,062 genes met a
strict statistical threshold for significance: a false discov-
ery rate (FDR) of 5% using Bonferroni correction for
multiple testing. Likewise, our analysis identified 1,834
and 106 genes in the pulmonary valve and pulmonary
artery, respectively with a 2-fold change in expression.
The large number of genes with changed expression in
the valve and ventricle relative to the artery may be a
reflection of the primary defect originating in these tis-
sues with secondary response in the artery. We com-
pared the list of genes with a 2-fold change from the
three tissues to identify genes in common (Figure 1).
Interestingly, the ventricle and pulmonary valve had 39
genes in common, and the pulmonary valve and artery
had 34 genes in common. However, there was only one
gene with a 2-fold change in expression in common
between the ventricle and the artery, and there were no
genes with a 2-fold change in expression shared by all
three tissues.
We used the expression data from the ventricle for
detectable probes (~26,000) in an average linkage K-
means clustering algorithm. The heat map (Figure 2)
shows the gene tree resulting from the analysis. In
Figure 2, five lanes on the right are from control sam-
ples and three lanes on the left are from patients with
22q11.2 deletion syndrome. The 16 subjects with TOF
clearly are clustered together compared to control sub-
jects, with the majority of the idiopathic subjects
grouped separately from the 22q11.2 deletion subjects.
In an attempt to separate patients into differing levels
of severity, we chose to group our patients based on
those that required early intervention with a modified
BT shunt placement (considered to be more severe),
and those that did not require early intervention before
complete surgical TOF correction. Within the group of
TOF subjects, seven required a BT shunt placement
early in life (red stars noted in Figure 2). These seven
subjects were part of a group of nine patients that sepa-
rate from the remaining TOF subjects. In general, a
Table 1 Summary data







Control 5 25265 na na
TOF 16 20801 715 347
DiGeorge 3 18329 88 18
1. Passed filter.
2. Statistically significant relative to controls.
na = not applicable.
Table 2 Mean relative expression of genes1 on 22q11.2
Gene Name Map 22q11.2 del TOF Control RefSeq
COMT 22q11.21-q11.23 0.36 (0.04) 1.02 (0.15) 0.96 (0.09) NM_000754; NM_007310
DGCR2 22q11.21 0.27 (0.10) 0.71 (0.23) 0.90 (0.25) NM_005137
CRYBA4 22q11.2-q13.1 0.54 (006). 0.86 (0.32) 1.01 (0.10) NM_001886
ZNF74 22q11.2 0.52 (0.01) 0.99 (0.12) 1.00 (0.15) NM_003426
FLJ36561 22q11.23 0.40 (0.24) 1.18 (0.44) 1.00 (0.21) NM_182520
CABIN1 22q11.23 0.52 (0.06) 0.53 (0.17) 0.99 (0.23) NM_012295
ARVCF 22q11.21 0.57 (0.07) 1.01 (0.44) 0.92 (0.24) NM_001670
FLJ14360 22q11.21 0.65 (0.08) 0.58 (0.17) 1.01 (0.13) NM_032775
RUTBC2 22q11.23 0.69 (0.04) 0.92 (0.42) 0.94 (0.16)
GGTLA1 22q11.23 0.58 (0.13) 0.61 (0.22) 0.98 (0.28) NM_004121
DGCR8 22q11.2 0.54 (0.11) 0.59 (0.25) 0.99 (0.11) NM_022720
GGT1 22q11.23 0.70 (0.36) 1.19 (0.32) 0.94 (0.26) NM_005265; NM_013421; NM_013430
MMP11 22q11.2 0.37 (0.18) 0.77 (0.33) 1.00 (0.17) NM_001145938
TBX1 22q11.21 Not detectable Not detectable Not detectable NM_005992
1. Expression levels from microarray (fold change) relative to the normalized control values set at 1, mean (+/- sd).
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common pattern of global gene expression was seen in
the TOF subjects differing from the controls, those sub-
jects considered to have more severe conotruncal
defects (those requiring early surgical intervention)
tended to have distinct patterns of gene expression pla-
cing them on distinct branches of the tree.
We identified 645 genes which had a 2-fold change in
expression between the severe and less severe groups
with FDR at 5% and Bonferroni multiple test correction.
The top canonical pathways identified included cardio-
myocyte differentiation via BMP (bone morphogenetic
protein). Two genes from this pathway, NPPA and
NPPB (natriuretic peptide precursor A and B) were
highly overexpressed in the TOF subjects relative to the
controls, but were five times higher in the less severe
TOF group relative to the early shunt group (Figure 2
shows a 3-fold and 15-fold change in less and more
severe TOF subjects, respectively, relative to control
subjects).
We have done ontological analysis of the 1,062 genes
with altered expression in the right ventricle using
Ingenuity Pathways Analysis software (Ingenuity Systems
Inc., Redwood City, CA), as well as GeneSpring software
and have identified several important relationships. The
list of genes contained a number of heart development
and function networks which were over represented.
The top five biofunction networks identified were: pro-
tein synthesis, cardiovascular disease, genetic disorder,
neurological disease, and cell death. The list of statisti-
cally significant canonical networks (Additional File 2,
Table S2) included WNT and Notch pathways; each
having several members with significantly altered
expression.
Because of our interest in determining the expression
patterns of other members of the WNT and Notch path-
ways, we used Ingenuity Pathways Analysis to visualize the
expression levels regardless of statistical significance.
[Additional files 3 and 4, Figures S1 and S2; green repre-
sents reduced expression (signal intensity) and red repre-
sents increased expression relative to the median of the
controls and Additional files 5 and 6, Tables S3 and S4,].
Interestingly, expression of most members of the networks
was reduced (green in the Additional files 3 and 4, Figures
S1 and S2) in the myocardium of our patients with TOF,
suggesting a pattern of mutational convergence leading to
a general suppression of gene expression in the right ven-
tricle of these developmentally important networks. As
can be seen in Additional files 3 and 4, Figures S1 and S2,
the expression levels in ventricular tissue for both net-
works were predominately downregulated relative to the
controls. The number of downregulated genes in each net-
work was significantly different from a discrete uniform
distribution. This would be expected if the upregulated
and downregulated genes were occurring by equal chance.
For example, 67/109 (62%) of units (genes) were green in
the WNT pathway (uncolored units were not counted as
they were not detectable on the microarray, also see Addi-
tional file 5, Table S3 for values of probes). The true pro-
portion of green units can be estimated to occur between
52% and 71%, with 95% confidence. Therefore, since a dis-
crete uniform distribution would result in an equal pro-
portion (50%) of green units (reduced expression relative
to controls) to red (increased expression), and since the
entire range of estimated values is greater than 50%, the
number of green units occurs more often than expected
by chance. A statistical test to determine if the proportion
Table 3 Comparison of QRT-PCR validation and microarray mean relative values1
Genbank Gene Symbol Map Microarray QRT-PCR Pathway
NM_178502 DTX3 12q13.2 0.57 (0.22) 0.63 (0.30) Notch
NM_004423 DVL3 3q27 0.38 (0.13) 0.53 (0.15) WNT
NM_030775 WNT5B 12p13.3 0.53 (0.14) 0.15 (0.51) WNT
NM_006172.3 NPPA 1p36.22 2.2 (0.59) (shunt) 19.4 (5.02) (no shunt) 2.1 (0.32) (shunt) 19.3 (0.82) (no shunt) BMP
1. Expression level (fold change) relative to the normalized control values set at 1, mean (+/- sd).
Figure 1 Venn diagram showing the number of genes in each
tissue with 2-fold changes in expression in the infants with
TOF relative to controls.
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of green was different from 50% was performed resulting
in a p-value of 0.017 indicating that the proportion of
green was significantly different from 50%. Likewise, the
analysis of the Notch pathway suggested that this pathway
was also suppressed (18/22, 82% units are green with a
p-value of 0.003, see Additional file 6, Table S4 for values
of probes). Interestingly, the Notch pathway was also sig-
nificantly suppressed in subjects with 22q11.2 deletions
(p = 0.014), suggesting a common outcome resulting from
different initiating parameters.
We attempted to evaluate if there was a general trend
toward downregulation of gene expression in develop-
mentally deficient tissues relative to normally developing
tissue. First we analyzed the general distribution pattern
of expression values in the TOF group and found no dif-
ference compared to the control subjects. Additionally,
Figure 2 Heat map with clustering based on all detectable genes in the right ventricle. * Infants requiring an early shunt (i.e., more severe).
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we examined several other pathways with comparable
numbers of units (e.g., Caviolar mediated endocytosis [51
units], Oncostatin M signaling [22 units], tight junction
signaling [106 units]) and found that they appear to have
a discrete uniform distribution (i.e., an equal chance of
reduced or increased expression relative to the control
values, data not shown). Thus, it appears that the sup-
pression of gene expression was confined to the WNT
and Notch pathways which are known to regulate devel-
opmental patterns in the heart.
We were interested in identifying genes which had
similar patterns of expression across the three tissues as
they may have related functions. We therefore took
expression values of all 2,932 genes with a significant
change in expression and derived nine clusters of genes
with similar expression patterns in the three tissues and
imported the list of genes in each group into Ingenuity
Pathways Analysis for ontological analysis. The resulting
nine classes of genes ranged in size from 119 to 684
members (Additional file 7, Table S5). Within the broad
category Physiological System Development and Func-
tion, cluster sets seven and eight had a statistically over-
represented group of genes involved in embryonic
development. Cluster sets one, six, seven and nine all
had significant numbers of genes involved in Cardiovas-
cular System Development and Function suggesting that,
in addition to having altered expression, many of these
genes appear to have similar patterns of expression
across the three tissues possibly signifying coordinated
function. Interestingly, cluster set three had a significant
group of genes from the Notch canonical pathway indi-
cating that the members of the Notch pathway had
similar expression patterns across these three tissues.
Discussion
Congenital heart defects are the most common type of
major birth defect, and account for the majority of mor-
bidity and mortality related to birth defects. The origin
of most congenital heart disease is thought to be multi-
factorial, implying contributions from anomalous gene
expression and epigenetic factors, as well as environ-
mental contributions.
Some of the genes involved in normal cardiogenesis
include transcription factors (e.g., NKX2.5, GATA-6,
GATA-4, HAND1, HAND2, and NF-ATC) which regu-
late the expression of genes in a tissue specific and
quantitative manner, as well as soluble factors including
bone morphogenic proteins (which acts as a positive
facilitator of nodal induction and left-right asymmetry),
transforming growth factor beta isoforms and fibroblast
growth factor isoforms (these may play a role in cardiac
hypoplasia) [22-24]. Many genes and networks identified
in lower animals have similar roles in human cardiogen-
esis. Study of animal models has greatly advanced our
understanding of the genetic mechanisms regulating
heart development. In spite of the expanding knowledge
of the genetic mechanisms involved in cardiac forma-
tion, there remain nearly 80% of children with congeni-
tal heart defects who do not have a known genetic
defect.
A previous study of gene expression in cardiac tissues
from a small number of children with TOF indicated
changed expression of several genes of potential impor-
tance including SNIP, A2BP1, and KIAA1437 [14] which
were upregulated, and genes markedly downregulated
included STK33, BRDG1, and TEKT. In addition,
another small study of gene expression in tissues from
children with TOF concluded that gene expression
changes in VEGF and altered levels of several ECM pro-
teins were contributory to TOF. Our data indicated that
the change of expression for these genes was in the
same direction as previously reported, although only
A2BP1 reached statistical significance in our analysis.
Our sample size was larger with more strict correction
procedures for multiple testing which may account for
these genes not reaching the statistical threshold in our
analysis.
Our data indicate that developmental deficiencies
resulting in conotruncal defects are associated with dis-
tinct changes in gene expression. Many of these genes
are involved in ameliorating the consequences of pul-
monary atresia/stenosis. However, we identified a strik-
ing collective suppression of genes in the WNT and
Notch pathways which are known to play critical roles
in cardiac development. Genetic mechanisms which
control embryonic heart formation are precisely regu-
lated, both temporally and spatially. We suggest that the
general downregulation of these pathways is an indica-
tion of faulty embryologic gene expression causing
imperfect cardiac development in these children.
The NPPA and NPPB genes are tightly linked on
human chromosome 1. During embryonic heart devel-
opment, chamber myocardium is derived from the myo-
cardium of the tubular heart and expression of the
NPPA gene, activated via the BMP pathway, is one of
the first hallmarks of heart chamber formation (OMIM,
108780). The NPPA and NPPB genes can also be acti-
vated by glucocorticoids and increased expression has
been associated with hypertrophy. Thus the activation of
these genes is associated with myocardial cellular prolif-
eration. The reduced expression of these two genes in
the group receiving an early shunt (considered to be
more severe) compared to the group not receiving a
shunt may be a biomarker for poorer conotruncal devel-
opment and perhaps poorer prognosis.
The genes associated with clustered gene sets seven
and eight, (Additional file 7, Table S5) containing
genes involved in embryonic development may also be
Bittel et al. BMC Medical Genomics 2011, 4:1
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important for further study as they may represent
altered pathways which may play a role in deficient spa-
tial patterning as the fetal heart was developing.
As was seen previously [14,15], many of the differen-
tially expressed genes were associated with compensation
relative to the conotruncal anomaly. However, we believe
we have identified a pattern of expression of develop-
mentally important networks (e.g., WNT and Notch sig-
naling networks) which supports the hypothesis that
converging and accumulating factors disrupt regulatory
networks controlling heart development during embryo-
logical development ultimately leading to tetralogy of Fal-
lot. Moreover, an apparently similar suppression of the
Notch pathway in children with 22q11.2 deletions (p =
0.014) suggests that factors leading to network suppres-
sion can arise from variable origins.
Conclusions
The moderate suppression of two pathways which are
important for heart development is consistent with the
hypothesis that many rare nonsynonymous variants, each
with a small impact (mutational loading), may accumu-
late and converge to dysregulate cardiac development.
These variants may be a consequence of genetic (protein
coding variants, promoter sequence changes or splicing
variants) or epigenetic modification (e.g., methylation
changes in CpG islands, histones or microRNA expres-
sion), which in summation could produce a shift in net-
work function to impair cardiac development. Our
observations suggest a more comprehensive genetic and
genomic analysis should be undertaken to identify candi-
date disturbances influencing pathway integrity.
Additional material
Additional file 1: Table S1. Estimates of intersample variability.
Estimates of the variation between samples.
Additional file 2: Table S2. Canonical pathways associated with
altered gene expression in TOF. List of pathways associated with
genes with changes expression in TOF relative to controls, p value and
gene names. Identified using Ingenuity Pathways Analysis (IPA).
Additional file 3: Figure S1, WNT pathway. WNT canonical pathway.
Color corresponds to increase (red) or decrease (green) in signal intensity
(expression) of genes in TOF subjects relative to control subjects
(developed using the Ingenuity Pathways Analysis program).
Additional file 4: Figure S2, Notch pathway. Notch canonical pathway.
Color corresponds to increase (red) or decrease (green) in signal intensity
(expression) of genes in TOF subjects relative to control subjects
(developed using the Ingenuity Pathways Analysis program).
Additional file 5: Table S3. List of genes in the WNT pathway with
fold change in TOF relative to controls. Complete list of genes from
the WNT pathway and the fold change in the right ventricle from
subjects with TOF relative to control subjects.
Additional file 6: Table S4. List of genes in the Notch pathway with
fold change in TOF relative to controls. Complete list of genes from
the Notch pathway and the fold change in the right ventricle from
subjects with TOF relative to control subjects.
Additional file 7: Table S5. Ontological analysis of genes with a
significant change of expression between subjects with TOF and
controls. Ontological analysis of clustered genes with a similar pattern of
expression across the three tissues examined (right ventricle, pulmonary
valve and pulmonary artery).
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